Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy
Open Access
- 3 January 2017
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 7, 167
Abstract
The pathogenesis of orbital Graves’ disease (GD), a process known as thyroid-associated ophthalmopathy (TAO), remains incompletely understood. The thyrotropin receptor (TSHR) represents the central autoantigen involved in GD and has been proposed as the thyroid antigen shared with the orbit that could explain the infiltration of immune cells into tissues surrounding the eye. Another cell-surface protein, insulin-like growth factor-I receptor (IGF-IR), has recently been proposed as a second antigen that participates in TAO by virtue of its interactions with anti-IGF-IR antibodies generated in GD, its apparent physical and functional complex formation with TSHR, and its necessary involvement in TSHR post-receptor signaling. The proposal that IGF-IR is involved in TAO has provoked substantial debate. Further, several studies from different laboratory groups, each using different experimental models, have yielded conflicting results. In this article, we attempt to summarize the biological characteristics of IGF-IR and TSHR and review the evidence supporting and refuting the postulate that IGF-IR is a self-antigen in GD and that it plays a potentially important role in TAO. The putative involvement of IGF-IR in disease pathogenesis carries substantial clinical implications. Specifically, blocking this receptor with monoclonal antibodies can dramatically attenuate the induction by TSH and pathogenic antibodies generated in GD of proinflammatory genes in cultured orbital fibroblasts and fibrocytes. These cell types appear critical to the development of TAO. These observations have led to the conduct of a now-completed multicenter therapeutic trial of a fully human monoclonal anti-IGF-IR blocking antibody in moderate to severe, active TAO.Keywords
Funding Information
- National Eye Institute (EY007002)
- National Institutes of Health (EY008976 and 5UM1AI110557)
This publication has 74 references indexed in Scilit:
- Insulin and its analogues and their affinities for the IGF1 receptorEndocrine-Related Cancer, 2012
- A Stimulatory Thyrotropin Receptor Antibody Enhances Hyaluronic Acid Synthesis in Graves' Orbital Fibroblasts: Inhibition by an IGF-I Receptor Blocking AntibodyThe Journal of Clinical Endocrinology & Metabolism, 2012
- A Fully Human, Allosteric Monoclonal Antibody That Activates the Insulin Receptor and Improves Glycemic ControlDiabetes, 2012
- Insulin-Like Growth Factor-I Regulation of Immune Function: A Potential Therapeutic Target in Autoimmune Diseases?Pharmacological Reviews, 2010
- Insulin and Insulin-like Growth Factor-1 Receptors Act as Ligand-specific Amplitude Modulators of a Common Pathway Regulating Gene TranscriptionJournal of Biological Chemistry, 2010
- Characterization of Thyrotropin Receptor Antibody-Induced Signaling CascadesEndocrinology, 2008
- Role of Ubiquitination in IGF-1 Receptor Signaling and DegradationPLOS ONE, 2007
- β-Arrestin and Mdm2 Mediate IGF-1 Receptor-stimulated ERK Activation and Cell Cycle ProgressionJournal of Biological Chemistry, 2007
- Signaling via the insulin-like growth factor-I receptor: Does it differ from insulin receptor signaling?Cytokine & Growth Factor Reviews, 1996
- Photoaffinity labelling of the TSH receptor on FRTL5, cellsFEBS Letters, 1987